ADH-1

• Description:

  ADH-1, an N-cadherin antagonist, inhibits N-cadherin mediated cell adhesion.

• UNSPSC:

  12352209

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  Cadherin

• Type:

  Peptides

• Related Pathways:

  Cytoskeleton

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/Exherin.html

• Purity:

  99.93

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  O=C([C@@H](NC([C@H](C(C)C)NC([C@H](C)NC([C@H](CC1=CN=CN1)N2)=O)=O)=O)CSSC[C@H](NC(C)=O)C2=O)N

• Molecular Formula:

  C22H34N8O6S2

• Molecular Weight:

  570.69

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Shintani Y, et al. ADH-1 suppresses N-cadherin-dependent pancreatic cancer progression. Int J Cancer. 2008 Jan 1;122 (1) :71-7.|[2]Li H, et al. ADH1, an N-cadherin inhibitor, evaluated in preclinical models of angiogenesis and androgen-independent prostate cancer. Anticancer Drugs. 2007 Jun;18 (5) :563-8.|[3]Turley RS, et al. Targeting N-cadherin increases vascular permeability and differentially activates AKT in melanoma. Ann Surg. 2015 Feb;261 (2) :368-77

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)

• Scientific Category:

  Peptides

• Clinical Information:

  Phase 2

• Citation 01:

  Biochem Biophys Res Commun. 2019 Oct 5. pii: S0006-291X (19) 31851-0. |bioRxiv. 2023 Jul 25:2023.07.22.550169.|bioRxiv. 2025 Oct 24.|Cell Death Dis. 2022 Jun 20;13 (6) :557.|iScience. 2024 Feb 6;27 (3) :109119.|J Cell Mol Med. 2022 Apr;26 (8) :2392-2403.|J Pain Res. 2020 Aug 12;13:2065-2072. |Oncogene. 2022 Nov;41 (46) :5020-5031.|Sci Rep. 2019 Feb 6;9 (1) :1517.|bioRxiv. 2025 Oct 3.

• CAS Number:

  [229971-81-7]